To date, five selective ATR inhibitors (berzosertib [16], ceralasertib [17], M4344 [18], RP-3500 [19], and BAY-1895344 [20]) have been forwarded to clinical trials to evaluate their effects on cancer treatment as a single agent or combination therapy (Figure 1). The gene discussed is ATR; the disease is cancer.